Project Overview
Diclofenac sodium slow release (SR) tablets 100mg are a pharmaceutical formulation designed to deliver the anti-inflammatory and analgesic effects of diclofenac sodium over an extended period. This slow release mechanism helps in reducing the frequency of dosage while maintaining therapeutic levels in the bloodstream, making it convenient for patients who require long-term treatment for conditions such as arthritis or postoperative pain. Diclofenac sodium acts by inhibiting the production of prostaglandins, which are compounds involved in inflammation and pain signaling. The SR formulation allows for a gradual release of the drug, enhancing patient compliance and minimizing gastrointestinal side effects associated with immediate-release formulations. Currently, the demand for slow-release formulations is increasing due to the growing preference for patient-centric treatment plans that improve overall medication adherence. With its proven efficacy and widespread acceptance in clinical settings, diclofenac sodium SR tablets hold significant promise in the pharmaceutical market, particularly within the pain management segment.
Market Potential
- Increasing prevalence of chronic pain and inflammatory conditions.
- Growing geriatric population requiring long-term pain management.
- Rising awareness about the benefits of slow-release formulations.
- Potential for expansion into emerging markets.
- Advancements in drug delivery technologies.
SWOT Analysis
Strengths
- Established efficacy of diclofenac in pain relief.
- Improved patient compliance due to reduced dosing frequency.
- Strong brand recognition in the pharmaceutical market.
Weaknesses
- Potential gastrointestinal side effects.
- Competition from other analgesics and treatment options.
- Dependency on regulatory approvals and guidelines.
Opportunities
- Expansion of product lines with different dosages or formulations.
- Strategic partnerships with healthcare providers for better market penetration.
- Increase in research and development for improved therapeutic applications.
Threats
- Regulatory challenges in different markets.
- Emerging generic competition affecting market share.
- Changes in healthcare policies and reimbursement frameworks.
Raw Materials Required
- Diclofenac sodium
- Hydroxypropyl methylcellulose (HPMC)
- Microcrystalline cellulose
- Magnesium stearate
- Lactose monohydrate
Investment Profiles & Financial Analysis
This project has 4 investment scales. Select a profile to view its figures.
Micro
Ideal for niche markets; potential for local demand.
Small
Good entry point for regional distribution; manageable scale.
Medium
Attractive for expanding market; higher production capacity.
Large
Strong market presence; scales well with increasing demands.
Frequently Asked Questions
What is this project about?
Diclofenac sodium slow release (SR) tablets 100mg are a pharmaceutical formulation designed to deliver the anti-inflammatory and analgesic effects of diclofenac sodium over an extended period. This slow release mechanism helps in reducing the frequency of dosage while maintaining therapeutic levels in the bloodstream, making it convenient for patients who require long-term treatment for conditions such as arthritis or postoperative pain. Diclofenac sodium acts by inhibiting the production of prostaglandins, which are compounds involved in inflammation and pain signaling. The SR formulation allows for a gradual release of the drug, enhancing patient compliance and minimizing gastrointestinal side effects associated with immediate-release formulations. Currently, the demand for slow-release formulations is increasing due to the growing preference for patient-centric treatment plans that improve overall medication adherence. With its proven efficacy and widespread acceptance in clinical settings, diclofenac sodium SR tablets hold significant promise in the pharmaceutical market, particularly within the pain management segment.
What is the market potential?
• Increasing prevalence of chronic pain and inflammatory conditions.
• Growing geriatric population requiring long-term pain management.
• Rising awareness about the benefits of slow-release formulations.
• Potential for expansion into emerging markets.
• Advancements in drug delivery technologies.
How much investment is required?
Total capital investment ranges from ₹2,250,000 to ₹79,200,000 depending on the scale of operation. This covers plant and machinery, civil work, pre-operative expenses, and working capital. Larger scales require proportionally higher investment but typically offer better returns.
When does this project break even?
At the larger investment scale, the expected break-even is approximately approx. 4 years at approximately 40.00% capacity utilisation. Smaller setups may reach break-even sooner due to lower fixed costs relative to the capacity.
What raw materials are required?
• Diclofenac sodium
• Hydroxypropyl methylcellulose (HPMC)
• Microcrystalline cellulose
• Magnesium stearate
• Lactose monohydrate
What are the key strengths of this project?
• Established efficacy of diclofenac in pain relief.
• Improved patient compliance due to reduced dosing frequency.
• Strong brand recognition in the pharmaceutical market.
Related topics